All news

Regeneron trades 9% below analyst target after EPS beat

Alpha Vantage · MarketBeat · · AI-summarised by FinFlash

Piper Sandler raised its Regeneron Pharmaceuticals price target to $865.00 from $854.00, keeping an overweight rating, implying roughly 10.7% upside from the current share price. The biopharma company recently beat analyst expectations with adjusted EPS of

Read original source

REGN company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.